DrugsControl Media Services

News Detail

SEC recommends approval for Astrazeneca's anti-hyperkalaemia drug Lokelma in India (05-03-2024)

New Delhi, 5 March 2024: The Subject Expert Committee (SEC) which advises the national drug regulator on drug approvals and clinical trials has recommended grant of permission to drug major Astrazeneca for import and marketing of two strengths of anti-hyperkalaemia therapy drug L......
View Details

Source : Pharmabiz
Subject Expert Committee SEC Astrazeneca anti-hyperkalaemia Lokelma sodium zirconium cyclosilicate end-stage kidney disease ESKD chronic haemodialysis

Related News